A polymorphism rs4705341 in the flanking region of miR- 143/145 predicts risk and prognosis of colorectal cancer

// Ruifen Sun 1, 2, 3, 4, * , Peng Chen 5, * , Lijuan Li 1, 5 , Hong Sun 1, 4 , Xinwen Nie 2 , Yundan Liang 1 , Fang Yuan 2 , Yan Pu 5 , Peng Bai 5 , Lin Zhang 1, 2, 4, 5 , Linbo Gao 1, 4 1 Laboratory of Molecular and Translational Medicine, West China Institute of Women and Children’s Health, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China 2 Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China 3 Central Laboratory, Yunnan University of Chinese Traditional Medicine, Yunnan, Kunming 650500, P.R. China 4 Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China 5 Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China * These authors have contributed equally to this work Correspondence to: Lin Zhang, email: zhanglin@scu.edu.cn Linbo Gao, email: gaolinboscu@163.com Keywords: miR-143/145, polymorphism, survival, colorectal cancer Received: January 28, 2016     Accepted: August 08, 2016     Published: August 19, 2016 ABSTRACT The aim of this study was to investigate the effect of a polymorphism rs4705341 in the flanking region of miR-143/145 on the risk of colorectal cancer (CRC). The rs4705341 polymorphism was analyzed in 1002 cases and 1062 controls using a polymerase chain reaction-restriction fragment length polymorphism method. We found a significantly reduced CRC susceptibility with miR-143/145 rs4705341 in homozygote comparison (adjusted OR = 0.66, 95%CI, 0.50-0.88, P = 0.004), dominant genetic model (adjusted OR = 0.80, 95%CI, 0.67-0.96, P = 0.015), recessive genetic model (adjusted OR = 0.73, 95%CI, 0.56-0.94, P = 0.016), and allele comparison (adjusted OR = 0.83, 95%CI, 0.73-0.94, P = 0.004). Stratification analysis showed that the rs4705341 was related to differentiated status, clinical stage I-II, and patients without lymph node metastasis. Moreover, patients with rs4705341GG had a longer overall survival (adjusted HR = 5.57, 95%CI, 0.95-32.68). These findings indicate that the miR-143/145 rs4705341 may be used as a potential biomarker for the development and prognosis of CRC.